Merdad V. Parsey M.D., Ph.D.
Net Worth

Last updated:

What is Merdad V. Parsey M.D., Ph.D. net worth?

The estimated net worth of Dr. Merdad V. Parsey M.D., Ph.D. is at least $50,977,878 as of 10 Dec 2024. He owns shares worth $9,502,198 as insider, has earned $22,225,680 from insider trading and has received compensation worth at least $19,250,000 in Gilead Sciences, Inc..

What is the salary of Merdad V. Parsey M.D., Ph.D.?

Dr. Merdad V. Parsey M.D., Ph.D. salary is $3,850,000 per year as Chief Medical Officer in Gilead Sciences, Inc..

How old is Merdad V. Parsey M.D., Ph.D.?

Dr. Merdad V. Parsey M.D., Ph.D. is 62 years old, born in 1963.

What stocks does Merdad V. Parsey M.D., Ph.D. currently own?

As insider, Dr. Merdad V. Parsey M.D., Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Gilead Sciences, Inc. (GILD) Chief Medical Officer 80,801 $117.6 $9,502,198

What does Gilead Sciences, Inc. do?

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

GILD logo
GILD
Gilead Sciences, Inc.
$117.6

Merdad V. Parsey M.D., Ph.D. insider trading

Gilead Sciences, Inc.

Dr. Merdad V. Parsey M.D., Ph.D. has made 19 insider trades between 2020-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 88,119 units of GILD stock on 27 Nov 2024. As of 10 Dec 2024 he still owns at least 80,801 units of GILD stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 3,820 N/A N/A
Option
Restricted Stock Unit 3,820 N/A N/A
Option
Non-qualified Stock Option (Right to Buy) 57,294 $57.92 $3,318,468
Sale
Common Stock 88,119 $92 $8,106,948
Option
Non-qualified Stock Option (Right to Buy) 88,119 $65.38 $5,761,220
Sale
Common Stock 5,200 $91.8 $477,381
Sale
Common Stock 3,199 $91.8 $293,678
Sale
Common Stock 57,294 $91.8 $5,259,303
Sale
Common Stock 10,399 $92 $956,708
Option
Common Stock 88,119 $65.38 $5,761,220
Option
Common Stock 57,294 $57.92 $3,318,468
Sale
Common Stock 20,590 $91.5 $1,883,985
Option
Common Stock 25,000 $57.92 $1,448,000
Option
Non-qualified Stock Option (Right to Buy) 25,000 $57.92 $1,448,000
Sale
Common Stock 5,000 $91.5 $457,500
Sale
Common Stock 2,000 $83.83 $167,660
Option
Non-qualified Stock Option (Right to Buy) 25,000 $57.92 $1,448,000
Sale
Common Stock 21,246 $84.5 $1,795,287
Option
Common Stock 25,000 $57.92 $1,448,000
Option
Common Stock 3,821 N/A N/A
Option
Restricted Stock Unit 3,821 N/A N/A
Sale
Common Stock 2,000 $68.63 $137,260
Option
Restricted Stock Unit 3,820 N/A N/A
Option
Common Stock 3,820 N/A N/A
Sale
Common Stock 2,000 $72.96 $145,920
Option
Restricted Stock Unit 6,946 N/A N/A
Option
Restricted Stock Unit 3,455 N/A N/A
Option
Common Stock 3,455 N/A N/A
Option
Common Stock 6,946 N/A N/A
Sale
Common Stock 8,230 $72.74 $598,626
Sale
Common Stock 2,000 $73.18 $146,360
Option
Restricted Stock Unit 2,779 N/A N/A
Option
Common Stock 2,779 N/A N/A
Sale
Common Stock 1,501 $76.99 $115,562
Option
Common Stock 2,779 N/A N/A
Option
Restricted Stock Unit 2,779 N/A N/A
Sale
Common Stock 1,485 $76.9 $114,197
Option
Common Stock 2,779 N/A N/A
Option
Restricted Stock Unit 2,779 N/A N/A
Sale
Common Stock 6,126 $78.99 $483,893
Option
Common Stock 7,999 N/A N/A
Option
Common Stock 3,455 N/A N/A
Option
Restricted Stock Unit 7,999 N/A N/A
Option
Restricted Stock Unit 3,455 N/A N/A
Sale
Common Stock 12,984 $79.96 $1,038,227
Sale
Common Stock 553 $85.33 $47,187
Option
Common Stock 1,039 N/A N/A
Option
Restricted Stock Unit 1,039 N/A N/A
Option
Common Stock 5,099 N/A N/A
Option
Restricted Stock Unit 5,099 N/A N/A
Option
Restricted Stock Unit 1,039 N/A N/A
Option
Common Stock 1,039 N/A N/A
Option
Common Stock 1,039 N/A N/A
Option
Restricted Stock Unit 1,039 N/A N/A
Option
Restricted Stock Unit 4,157 N/A N/A
Option
Restricted Stock Unit 3,455 N/A N/A
Option
Common Stock 3,455 N/A N/A
Option
Common Stock 4,157 N/A N/A
Option
Common Stock 5,100 N/A N/A
Option
Restricted Stock Unit 5,100 N/A N/A
Option
Restricted Stock Unit 3,455 N/A N/A
Option
Common Stock 3,455 N/A N/A
Option
Restricted Stock Unit 5,101 N/A N/A
Option
Common Stock 5,101 N/A N/A
Sale
Common Stock 182 N/A N/A

Gilead Sciences key executives

Gilead Sciences, Inc. executives and other stock owners filed with the SEC: